Search research articles
Contact Us
Filters
Showing results (121-130 of 196) with videos related to
Page
of 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2025
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial
Jose Luis Sandoval, Nicolas Kiavue, Lounes Djerroudi, et al.
International Journal of Cancer
|
November 8, 2022
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity
Lindsay B Alcaraz, Aude Mallavialle, Caroline Mollevi, et al.
Bulletin Du Cancer
|
July 6, 2011
[Node negative breast cancer. Beyond international consensus: a pragmatic approach]
Frédérique Penault-Llorca, David Coeffic, Thierry Delozier, et al.
Frontiers in Oncology
|
April 3, 2023
<i>BRCA1</i>-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
Carolina Velazquez, Esin Orhan, Imene Tabet, et al.
Breast Cancer Research and Treatment
|
July 13, 2019
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy
William Jacot, Florence Dalenc, Evelyne Lopez-Crapez, et al.
Pharmaceutics
|
April 23, 2022
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, et al.
Histopathology
|
May 9, 2015
Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing
Nicola Fusco, Pierre-Emmanuel Colombo, Luciano G Martelotto, et al.
The Lancet. Oncology
|
February 19, 2013
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
John Fr Robertson, Jean-Marc Ferrero, Hugues Bourgeois, et al.
Annales De Pathologie
|
December 17, 2011
[Neoadjuvant treatment of breast cancer: implications for the pathologist]
Sophie Le Guellec, Romain Perallon, Jean-Philippe Alunni, et al.
JAMA Oncology
|
September 25, 2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial
Fatima Cardoso, William Jacot, Sherko Kuemmel, et al.
Page
of 20
Search research articles
Search
Showing results (121-130 of 196) with videos related to
Sort By:
Page
of 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2025
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial
Jose Luis Sandoval, Nicolas Kiavue, Lounes Djerroudi, et al.
International Journal of Cancer
|
November 8, 2022
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity
Lindsay B Alcaraz, Aude Mallavialle, Caroline Mollevi, et al.
Bulletin Du Cancer
|
July 6, 2011
[Node negative breast cancer. Beyond international consensus: a pragmatic approach]
Frédérique Penault-Llorca, David Coeffic, Thierry Delozier, et al.
Frontiers in Oncology
|
April 3, 2023
<i>BRCA1</i>-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
Carolina Velazquez, Esin Orhan, Imene Tabet, et al.
Breast Cancer Research and Treatment
|
July 13, 2019
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy
William Jacot, Florence Dalenc, Evelyne Lopez-Crapez, et al.
Pharmaceutics
|
April 23, 2022
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, et al.
Histopathology
|
May 9, 2015
Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing
Nicola Fusco, Pierre-Emmanuel Colombo, Luciano G Martelotto, et al.
The Lancet. Oncology
|
February 19, 2013
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
John Fr Robertson, Jean-Marc Ferrero, Hugues Bourgeois, et al.
Annales De Pathologie
|
December 17, 2011
[Neoadjuvant treatment of breast cancer: implications for the pathologist]
Sophie Le Guellec, Romain Perallon, Jean-Philippe Alunni, et al.
JAMA Oncology
|
September 25, 2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial
Fatima Cardoso, William Jacot, Sherko Kuemmel, et al.
Page
of 20